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Abstract
Background: Enprocal is a high-protein micro-nutrient rich formulated supplementary food
designed to meet the nutritional needs of the frail elderly and be delivered to them in every day
foods. We studied the potential of Enprocal to improve gut and immune health using simple and
robust bioassays for gut cell proliferation, intestinal integrity/permeability, immunomodulatory,
anti-inflammatory and anti-oxidative activities. Effects of Enprocal were compared with whey
protein concentrate 80 (WPC), heat treated skim milk powder, and other commercially available
milk derived products.
Results: Enprocal (undigested) and digested (Enprocal D) selectively enhanced cell proliferation in
normal human intestinal epithelial cells (FHs74-Int) and showed no cytotoxicity. In a dose
dependent manner Enprocal induced cell death in Caco-2 cells (human colon adencarcinoma
epithelial cells). Digested Enprocal (Enprocal D: gut enzyme cocktail treated) maintained the
intestinal integrity in transepithelial resistance (TEER) assay, increased the permeability of
horseradish peroxidase (HRP) and did not induce oxidative stress to the gut epithelial cells.
Enprocal D upregulated the surface expression of co-stimulatory (CD40, CD86, CD80), MHC I
and MHC II molecules on PMA differentiated THP-1 macrophages in coculture transwell model,
and inhibited the monocyte/lymphocyte (THP-1/Jurkat E6-1 cells)-epithelial cell adhesion. In
cytokine secretion analyses, Enprocal D down-regulated the secretion of proinflammatory
cytokines (IL-1β and TNF-α) and up-regulated IFN-γ, IL-2 and IL-10.
Conclusion: Our results indicate that Enprocal creates neither oxidative injury nor cytotoxicity,
stimulates normal gut cell proliferation, up regulates immune cell activation markers and may aid in
the production of antibodies. Furthermore, through downregulation of proinflammatory cytokines,
Enprocal appears to be beneficial in reducing the effects of chronic gut inflammatory diseases such
as inflammatory bowel disease (IBD). Stimulation of normal human fetal intestinal cell proliferation
without cell cytotoxicity indicates it may also be given as infant food particularly for premature
babies.
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The ability to eat sufficient amounts orally is inversely
associated with the extent of frailty and studies have indi-
cated that nutritional intake is often compromised in the
elderly [1]. Poor gut health and secondary health issues as
a consequence are matters of nutritional attention for the
elderly, infants and immune compromised persons. Diet
is a factor that can be extremely varied in terms of quan-
tity, quality, frequency and duration of meals in individu-
als, but that can also be modified with targeted dietary
interventions to produce the best results for any individ-
ual [2]. Diets of the elderly are generally low in protein,
low in energy and deficient in a range of micro-nutrients
[1,3,4]. High protein diets, in particular those based on
whey proteins, are being marketed to improve the health
status of the elderly [4] as well as other target groups e.g.
athletes and babies. Furthermore micro-nutrients includ-
ing anti-oxidants e.g. Vitamins A, C and zinc are also
being used for fortification or as dietary supplements for
healthy older patients [5]. There are growing number of
compositional foods under development, being patented
or emerging in the market that target specific nutritional
deficiencies beyond the traditional infant formula market.
Recent examples include WO2007/070754 a high protein
dietary supplement for treating various diseases associ-
ated with protein deficiency (Novalife); and WO2007/
022991 compositions for enhancing vascular integrity,
cellular survival and reducing apoptosis in ischema
(Nestec).
Enprocal, a recently formulated supplementary food is
designed to meet the nutritional needs of the frail elderly
and to be delivered to them in common every day foods.
Enprocal's formulation was developed by specialised aged
care dieticians and a food scientist experienced in powder
based food supplements. The ingredients of Enprocal
such as dairy-based proteins (whey protein concentrate,
skim milk powder, whole milk powder), vitamins and
minerals (including calcium, zinc and vitamins C, D, B
group and A), vegetable oils and inulin (fibre) were
selected to meet the nutritional profile of elderly specified
though dietetic input (Table 1). With whey protein con-
centrate (WPC) (80% protein) as its key ingredient it pro-
vides i) the highest-quality protein (as measured by
protein efficiency ratio (PER), ii) rapid protein digestion,
iii) essential amino acids, in particular cysteine, threonine
and leucine that may be required in increased levels in the
elderly [6,7], iv) cysteine to improve glutathione status
and muscle protein synthesis, v) high concentrations of
branched chain amino acids, and vi) minor bioactive
components such as immuno-globulins, growth factors,
and anti-microbial proteins and peptides to assist in effec-
tive gut function [6,8-12]. Today, whey is a popular die-
tary protein supplement purported to provide
antimicrobial activity, immune modulation, improved
muscle strength and body composition, and to prevent
cardiovascular disease and osteoporosis [reviewed in
[8,11,12]]. Enprocal with WPC as its key ingredient there-
fore contains high levels of constituent proteins including
beta-lactoglobulin, alpha-lactalbumin, lactoferrin, lac-
toperoxidase and glycomacropeptide which have been
demonstrated a range of immune-enhancing properties
[11,12]. In addition, whey has the ability to act as an anti-
oxidant, antihypertensive, antitumor, hypolipidemic,
antiviral, antibacterial, and chelating agent [6,8,11,12].
Whey proteins have been reported to enhance digestion
and gut function [8,11-13] as well as glutathione produc-
tion and immune function, hence increasing dietary avail-
ability may promote general health in a variety of ways
[14,15].
Developing and maintaining a healthy intestinal tract is a
pre-requisite for general health and aiding disease preven-
tion. The gut epithelial cells lining of the intestinal lumen
Table 1: Composition of Enprocal.
Ingredients Composition per 100 g
Whey protein concentrate 41.4 g
Vegetable fibre (inulin) 10.2 g
Vegetable oil 8.2 g
Vitamin A 548 μg
Thiamin (Vitamin B1) 0.8 mg
Riboflavin (Vitamin B2) 1.9 mg
Folate 173 μg
Vitamin B6 1.0 mg
Vitamin B12 2.9 μg
Vitamin C 57 mg
Vitamin D 9 μg
Vitamin E 4.2 mg
Calcium 1142 mg
Iron 3.9 mg
Magnesium 232 mg
Phosphorus 780 mg
Zinc 10.7 mgPage 2 of 19
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and the rest of the body. It is at this interface that nutri-
tion, environment and genetics come together to deter-
mine gut health. The intestinal mucosa is lined by a
monolayer of intestinal epithelial cells joined together at
their apical poles by tight junctions, and supported by an
extensive and complex immune system and transcellular
pathways for nutrient absorption [16]. The mucosal sur-
face of the gastrointestinal tract forms a barrier that sepa-
rates the luminal contents from the effector immune cells
underneath. With the emergence of the concept of immu-
nophysiology, it is clear that the function of the intestinal
epithelium is affected by many immune cell types [17].
Any abnormal activation of such immune cells (macro-
phages) overproduces the inflammatory cytokines e.g.,
tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-
6 that cause destructive cell damage to the intestinal epi-
thelial monolayers and subsequent mucosal inflamma-
tion leading to inflammatory bowel disease (IBD) such as
Crohn's disease (CD) and ulcerative colitis (UC) [18,19].
Cellular injury from reactive oxygen species (ROS) is
implicated in a wide variety of gut diseases and pathologic
conditions [20]. There is a growing body of evidence that
oxidative stress may contribute to gut inflammation,
ulcers, inflammatory bowel disease, and leaky gut syn-
drome. Newborn and the elderly are more prone to oxi-
dant injury [20-22].
The present study was aimed to assess the potential of
Enprocal to improve gut and immune health functions.
We investigated specifically whether Enprocal, after diges-
tion with a cocktail of gut enzymes maintained gut cell
proliferation and mucosal integrity, possessed immu-
nomodulatory (monocyte/macrophage and T cell activa-
tion and cytokine production), anti-inflammatory
(immune-gut cell adhesion) and anti-oxidative proper-
ties. We sought to achieve conditions as close as possible
to those of the human digestive tract by employing in
vitro, most widely used human gut epithelial cells alone
(Caco-2 and FHS Int 74) or in coculture with human
immune THP-1 (monocytes) and Jurkat (T lymphocytes)
cells in transwell system.
FHs 74 Int and Caco-2 cell lines used worldwide by the
researchers were employed as the models of human intes-
tinal epithelial cells in the study. FHs 74-Int cells, used in
the study were although derived from normal human fetal
intestine but have been reported to show mature epithe-
lial-like characteristics [23]. The growth-promoting activi-
ties of EGF, TGF-α IGF-I and insulin were examined using
the same intestinal cells [24]. Caco-2 cells (derived from
human colon adenocarcinoma) have gained enormous
popularity as a reliable and high-throughput in vitro
model system for the study of human intestinal permea-
bility and evaluation of a large number of drug candidates
for their intestinal absorption [25,26]. For orally adminis-
tered compounds, permeability through Caco-2 cell mon-
olayers correlates well with human in vivo absorption [26-
28]. Caco-2 monolayers can display electrical properties
typical of either small intestinal or colonic enterocytes
[27]. Caco-2 cells are able to differentiate spontaneously
in culture and display a small intestine-like (villus) phe-
notype. The differentiated cells polarise, form microvilli
and secrete enzymes associated with the enterocyte brush
border such as sucrase-isomaltase, alkaline phosphatase,
alkaline phosphatase, lactase and aminopeptidase [29].
This cell line thus represents an appropriate model for the
study of transport mechanisms related to the intestinal
barrier and for investigating diverse problems of nutrients
bioavailability and absorption without concern for differ-
ences between human and animals [30].
Our study, provides the first report on the bioactivity of
digested Enprocal components which may be released
through enzymatic action from its key ingredients such as
whey protein concentrate for gut epithelial cell growth,
integrity, absorptive, immunomodulatory, anti-inflam-
matory and anti-oxidative properties.
Results
Digested Enprocal (Enprocal D) maintains cell growth, 
enhances cell proliferation and shows no cytotoxicity in 
normal human intestinal epithelial cells
Near complete digestion of Enprocal and other digested
milk product controls was achieved after 4 hours incuba-
tion with gut enzyme cocktail mixture (Fig 1). In our pre-
liminary experiments we treated Enprocal with the gut
enzyme cocktail at different enzyme cocktail: protein
ratios at pH 7.0–7.4. A 1:50 ratio of enzyme cocktail: pro-
tein at pH 7.2 was found to be most optimal and complete
digestion was achieved after 6 hours. Further it was
deemed necessary to find a concentration range which
would not kill/disrupt the cell monolayers needed to test
in bioassays on permeability, immunomodulation, cell
adhesion, and oxidative stress. We treated Caco-2 and FHs
74 Int cells with digested and undigested samples of
Enprocal at different concentrations (100–8000 μg/ml) to
determine the effect on cell viability and growth deter-
mined by trypan blue exclusion assay (Fig 2A). With both
Enprocal undigested and digested samples, the Caco-2
cell viability as compared to that of FHs 74 Int was signif-
icantly reduced in (P < 0.001) at concentrations 4000 and
8000 μg/ml. There was visible reduction in Caco-2 viabil-
ity with Enprocal D compared to undigested Enprocal.
However, these levels did not reach any significance.
There was no effect of all concentrations tested in the
range of 100–8000 μg/ml on the cell viability of normal
intestinal FHs 74 Int cells. This was further confirmed in
the LDH released cytotoxicity assay (Fig 2B). There was no
significant increase (P > 0.05) in the cytotoxicity as com-Page 3 of 19
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treated with digested and undigested samples of Enprocal
from 100–8000 μg/ml. The enzyme cocktail showed no
effect of its own on cell viability and cytotoxicity in both
the cell lines. Although there was no significant difference
between the cell viability and cytotoxicity effects of
digested and undigested Enprocal samples but to mimic
the in vivo system we selected the digested form for bio-
assays. From the cell viability and cell cytotoxicity results
500–2000 μg/ml was selected as the optimal concentra-
tion range for the bioassays. The other control milk prod-
uct digests at these concentrations were tested for their
effects on cell viability in trypan blue assay (Fig 2C).
When compared to media only control (no treatment)
and Enprocal D, heat SMP digest samples reduced signifi-
cantly (P < 0.001) the Caco-2 cell viability at 2000 μg/ml.
The control milk products were further tested in LDH
release assay (Fig 3A), and cytotoxicity levels were below
10% and not significant (P > 0.05) at 2000 μg/ml concen-
tration when compared with Enprocal D and media only
control. In TUNEL and Annexin-V-fluos assays, Enprocal
D did not significantly (P > 0.05) increase the apoptotic
index (AI) and necrotic index (NI), however heat SMP
induced significant (P < 0.01) AI as compared to media
only control in Caco-2 cells (Fig 3B). In a dose dependent
manner (500–4000 μg/ml) Enprocal D increased signifi-
cantly (P < 0.001) the proliferation of FHs 74 Int cells
(Figure 4), determined by MTT assay, as compared to
untreated and positive control (EGF 50 ng/ml) cells.
When compared with other control products this effect
was significant (p < 0.001) except for P2 (500 μg/ml)
where the difference was insignificant between Enprocal
and P2. However the cell proliferation of Caco-2 cells was
decreased significantly following treatment with Enprocal
D (data not shown).
Enprocal D maintains the mucosal integrity, increases the 
expression of ZO-2 (tight junction protein) and 
macromolecular absorption
Intestinal Caco-2 monolayers grown on Millipore cell cul-
ture inserts in transwell system were used to measure the
transepithelial resistance (TEER) following treatments
with Enprocal D and other digested milk product controls
at a concentration of 500 μg/ml (Fig 5A). At 0 hour before
treatment, the Caco-2 monolayers after 21 days of growth
were found to be fully differentiated to enterocytes and
polarized, continuous without any gaps and displayed
TEER values 520 ± 20 ohm.cm2 in control growth media.
Figure 5A showed the TEER values of cell monolayers fol-
lowing different treatments relative to control (media
only). The most significant (P < 0.01) decrease was
observed in all treatments after the first 6 hours except for
Enprocal D and P2 (P > 0.05). Both P2 and Enprocal D
were able to recover the TEER values at 12 hours and the
increase was maintained further till 48 hours duration
(end of experiment) as compared to other control milk
products. However, TEER resistance values for Enprocal D
were found to increase further after 24 hours. P1 was
found to decrease significantly (P < 0.001) the TEER after
24 hours. The gut enzyme cocktail had no effect on the
TEER when compared with media only control. The Tri-
ton-X, known to disrupt the cell monolayer, was used as
the positive control. It reduced significantly (P < 0.001)
the TEER resistance at 6 hours which were not recovered
throughout the experimental period. The monolayer
integrity results were further confirmed by expression of
tight junction protein -ZO-2. Figure 5B shows an upregu-
lation of ZO-2 expression on Caco-2 monolayers treated
with 500 μg/ml of Enprocal and P2 digests for 12 hours.
SDS-PAGE analysis of Enprocal and whey protein concen-trate (WPC) digested with gut enzyme cocktail (pH7.2) for 4 hoursFigure 1
SDS-PAGE analysis of Enprocal and whey protein 
concentrate (WPC) digested with gut enzyme cock-
tail (pH7.2) for 4 hours.
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Cell viability (A), Cell cytotoxicity (B) of Caco-2 and normal human FHs74-Int cells treated with undigested and digested Enprocal (Enprocal D) 100–8000 μg/ml of each for 48 hoursFigure 2
Cell viability (A), Cell cytotoxicity (B) of Caco-2 and normal human FHs74-Int cells treated with undigested 
and digested Enprocal (Enprocal D) 100–8000 μg/ml of each for 48 hours. Cell viability was determined by trypan 
blue exclusion assay. Cell cytotoxicity was determined by LDH release assay. (C) Cell viability (trypan blue exclusion assay) of 
Caco-2 monolayers treated with Enprocal D (500–2000 μg/ml) and with other digested milk product controls. All treatments 
were performed in triplicate and assay was repeated three times independently with similar results. The mean for representa-
tive experiment was calculated and presented as a mean ± SD values. ** Indicates a highly significant P < 0.001 value from the 
control with media only. *Indicates a significant P < 0.05 value from the control with media only.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7In Horseradish Peroxidase (HRP) flux assay, Enprocal D
aided macromolecular transport through the Caco-2 cell
monolayer (Table 2). HRP flow through increased with
time after treatment with Enprocal D and other milk prod-
uct digests. After 4 hours significant (P < 0.05) HRP flux
increase (1.5 fold) as compared to media only control was
observed in Enprocal treated cells which increased further
to 2 and 3.9 fold after 8 and 16 hours respectively. Among
other products 1.5, 1.8, 1.3 and 2.1 fold increase was
observed for heat SMP, WPC, P1 and P2 respectively at 8
hours while significant (P < 0.001) increase, 2, 2.4, 2.6
and 4.4 fold occurred at 16 hours for heat SMP, WPC, P1
and P2 respectively. As expected the positive control Tri-
ton X, showed 9.7 fold increases at 4 hours which
remained consistent till 16 hours. The enzyme cocktail
mixture had no effect when compared with untreated
cells.
Anti-oxidant activities of Enprocal D
We examined the levels of AOE activities in Caco-2 cells
treated with Enprocal D and compared with other control
commercial milk product (WPC and P2) digests. There
was no significant change in the activities of either CuZn-
SOD or MnSOD in Enprocal D and WPC treated cells as
compared to vitamin C (positive control) treated cells
(Fig. 6A). This indicates that while Enprocal D did not
induce oxidative stress in the gut cells, P2 treatment led to
highly significant (P < 0.001) increase in the activities of
these enzymes indicating that it is inducing an oxidative
stress response. Increased SOD activity if not accompa-
nied by similar levels of other AOEs may be harmful.
Activity levels for CAT were not significantly (P > 0.05)
effected by the treatments with Enprocal, WPC and P2.
However activity levels for GPx increased significantly (P
< 0.01) after treatment with P2 digest (Fig 6B).
Cell cytotoxicity determined by LDH release assay (A) and cel  death (apoptosis/necrosis) (B) following treatment with 500–2000 μg/ml f Enprocal D and th r digested milk prod-uct con rolsFigure 3
Cell cytotoxicity determined by LDH release assay 
(A) and cell death (apoptosis/necrosis) (B) following 
treatment with 500–2000 μg/ml of Enprocal D and 
other digested milk product controls. Cells were 
treated for 48 hours with milk products and stained by 
TUNEL analysis for apoptotic cells, Annexin-V-fluos analysis 
and counterstained with propidium iodide to reveal necrotic 
cells. Cell death is shown here in terms of apoptotic (A/I) and 
necrotic indices (N/I). All treatments were performed in trip-
licate and assay was repeated three times independently with 
similar results. The mean for representative experiment was 
calculated and presented as a mean ± SD values. ** Indicates 
a highly significant P < 0.001 value from the control with 
media only. *Indicates a significant P < 0.05 value from the 
control with media only.
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Effect of Enprocal D and other digested milk product con-trols on cell proliferation of normal human intestinal cells (FH 74-Int) determined by MTT assayFigure 4
Effect of Enprocal D and other digested milk product 
controls on cell proliferation of normal human intes-
tinal cells (FHs74-Int) determined by MTT assay. All 
treatments were performed in triplicate and assay was 
repeated three times independently with similar results. Each 
bar presented in the histogram was mean ± SD values of all 
experiments in triplicates. **P < 0.001 is the highly significant 
value from the control with media only or enzyme cocktail. 
*P < 0.05 is the significance value from the control with 
media only or enzyme cocktail.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7Enprocal D upregulates the surface expression of co-
stimulatory CD40, CD86, CD80 MHC I & MHC II on 
human macrophages and inhibits the monocyte/
lymphocyte-epithelial cell adhesion
In a transwell coculture model of Caco-2 and PMA differ-
entiated THP-1 macrophages, movement of bioactive
components of with Enprocal D and other digested milk
product controls from mucosal (apical wells with Caco-2
monolayers) to serosal (basolateral wells containing PMA
differentiated THP-1 macrophages) induced up-regula-
tion of CD40, CD80, CD86 and MHC-I & II expression on
THP-1 macrophages in a manner similar to that of
immune stimulant IFN-γ (Fig 7A &7B). Although THP-1
macrophages showed no expression of activation markers
in response to the negative control (no treatment; cells in
culture medium alone), they strongly up-regulated expres-
sion of CD40 (P < 0.001), CD86 (P < 0.001), CD80 (P <
0.001), and MHC I & II (P< 0.001) on the cell surface
upon treatment with Enprocal D, other digested milk
product controls compared to no treatment control. The
response observed was maximal with Enprocal D.
Enprocal D in a dose dependant manner significantly (P <
0.001) inhibited the adhesion of lymphocytes and mono-
cytes to Caco-2 cells. Similar levels of inhibition of adhe-
sion were observed with P2 (Fig 8A &8B).
Enprocal D modulates the cytokine response in human 
immune cells (down-regulates the proinflammatory 
cytokines TNF-a and Il-1β and up-regulates Il-2, IL-10 and 
IFN-γ)
The levels of proinflammatory (TNF-α and IL-1 β), both
Th1 (IFN-γ and IL-2) and Th2 (IL-6 and IL-10) cytokines
and chemokine IL-8 were measured in cell culture super-
nates of THP-1 (LPS stimulated) and Jurkat E6-1 cells.
These immune cells were grown in lower (basolateral)
wells of transwell coculture models of Caco-2 and THP-1
Caco-2 and Jurkat E6-1 cells. As shown in Table 3 the
cytokine modulatory effect upon movement of bioactive
components of Enprocal D and other digested milk prod-
uct controls from mucosal (apical wells with Caco-2 mon-
olayers) to serosal (lower basolateral wells) was evident.
All the cytokine levels in the growth media samples and
untreated cells were below the detection limits of ELISA.
The cytokines response induced in the LPS only stimu-
lated cells was highly significant (p < 0.001) as compared
to non-stimulated cells and considered 100%. The levels
of LPS stimulated TNF-α, IL-1β and IL-6 were reduced dra-
matically by 91%, 57% and 44% respectively after treating
cells with Enprocal D as compared to LPS only control.
WPC similarly reduced the levels by 85%, 75% and 84%
for TNF-α, IL-1β and IL-6 respectively. However, with P2
control product levels of TNF-α and IL-6 were either neg-
ligible or below detection limits and it decreased the levels
by 87% for IL-1 β. There was no effect on IL-8 production
by any of the products tested as compared to maximal
response. When compared with the positive control
Effect of Enprocal D and other digested milk product con-trols on transepitheli l electrical r sistance (TEER) (A), tight juncti protein-ZO-2 xpression (immunofluorescen e in confocal mic scopy) (B)Figure 5
Effect of Enprocal D and other digested milk product 
controls on transepithelial electrical resistance 
(TEER) (A), tight junction protein-ZO-2 expression 
(immunofluorescence in confocal microscopy) (B). 
Caco-2 monolayers (21 day old, differentiated cells) were 
incubated with 500 μg/ml of test samples and control (no 
treatment) for 48 hours as indicated. All treatments were 
performed in triplicate and assay was repeated three times 
independently with similar results. The effect on epithelial 
barrier integrity was measured (TEER results in ohms-cm2) 
and mean ± SD to relative TEER values were calculated with 
respect to media only controls and plotted. Significant differ-
ences (*P, < 0.05) and highly significant differences (**P, < 
0.001) between the relative TEER levels as compared to con-
trol cells are indicated by asterisks.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7(PMA) Enprocal D treatment increased levels of IFN-γ by
29%, while both WPC and P2 decreased the levels of IFN-
γ by 51% and 88% respectively in the supernates of Jurkat
E6-1 cells. Enprocal D treatment increased levels of IL-10
by 48% compared with control PMA stimulated cells and
WPC and P2 increased IL-10 by 26% and 15% respec-
tively. Both Enprocal D and WPC induced IL-2 secretion
in non-stimulated Jurkat cells to nearly the same (905 ±
12 pg/ml and 925 ± 12 pg/ml respectively) levels as were
achieved with PMA stimulated cells (positive) control
(955 ± 15 pg/ml). With P2 digest treatment the IL-2 secre-
tion levels were decreased by 56% when compared with
positive (PMA stimulated cells) control (100%).
Discussion
In the present study, we reported for the first time the
potential of Enprocal to improve gut and immune health.
In the past decade, it has become clear that much of the
gastrointestinal tract maintains youthful function well
into the eighth and ninth decade of life. There is little dif-
ference between a 20 year-old and an 80 year-old in the
quantity and quality of biliary, pancreatic and intestinal
secretions, in the absorptive capacity of the small intes-
tine, and general nutritional requirements [31]. In practi-
cal terms in gut health, swallowing and defecation are the
two most likely functions to be affected by aging [31]. The
areas at greatest risk of developing aging-related dysfunc-
tion are the upper GI tract, particularly the oropharynx
and esophagus, and the distal tract (colon and rectum).
The inability to eat sufficient amounts orally leads to an
often compromised nutritional intake in the elderly. Their
diets are low in protein, low in energy (more specifically
energy density) and deficient in micronutrients [1,3,4]
and elderly gut slows the absorption of nutrients from the
gut lumen have also been reported [1,3]. Enprocal is a for-
mulated supplement developed to meet the nutritional
profile of elderly and contains whey protein concentrate,
skim milk powder, whole milk powder, vitamins and
minerals (including calcium, zinc and vitamins C, D, B
group and A), vegetable oils and inulin (fibre).
Enprocal D helps in gut cell growth, maintains gut barrier 
function and mucosal-integrity
Although not mimicking the ageing gut epithelium, FHs
74 Int and Caco-2 cell lines are employed world wide as
suitable cell culture models displaying enterocyte like dif-
ferentiation for studying the proliferation and gut integ-
rity/permeability and immunomodulation at cellular
level [23-30,32,33]. We first determined a concentration
range of Enprocal, which was not cytotoxic (kill/disrupt)
to the Caco-2 cell monolayers, needed to test the down-
stream intestinal permeability assays, adhesion assays etc.
We used initially both undigested versus digested Enpro-
cal to determine if there was any difference between the
effects of two upon treatment with gut cocktail mixture on
cell viability. Both digested and undigested Enprocal had
no affect on Caco-2 cell viability over a dose range of 500–
2000 μg/ml and this concentration range was chosen for
bioassays. Since Enprocal is a dietary supplement to be
taken orally and to mimic conditions as close as possible
Table 2: Effect of Enprocal D and other digested milk product controls on macromolecular absorption determined by Horseradish 
Peroxidase (HRP) flux assay.
Ingredients 4 hr (Mean ± SD) 8 hr (Mean ± SD) 16 hr (Mean ± SD)
Enprocal 12.5 ± 1.8* 17.5 ± 1.3* 35.5 ± 1.6**
WPC 7.9 ± 0.74 15.6 ± 0.7* 22.2 ± 0.7**
P1 6.5 ± 0.8 10.9 ± 0.6 24.5 ± 0.7**
P2 10.5 ± 1.4 18.5 ± 1.2* 40.4 ± 1.3**
Heat SMP 8.5 ± 0.6 12.4 ± 0.5 18.4 ± 0.5**
No treatment 8.3 ± 1.3 8.5 ± 1.1 9.1 ± 2.6
Enzyme cocktail 8.5 ± 1.2 8.5 ± 1.2 8.7 ± 1.3
Triton-X 100 80.5 ± 2.8** 85.3 ± 2.5** 88.5 ± 2.6**
HRP flux results are shown in percentage for 4–16 hours determined in the basolateral compartment. All samples were assayed in three 
independent assays each performed in triplicate and the mean for all experiments was calculated and presented as a mean ± SD values.
** Indicates a highly significant P < 0.001 value from the control with media only (no treatment).
*Indicates a significant P < 0.05 value from the control with media only (no treatment). Triton-X 100 is a known cell disruptor and act as a positive 
control in HRP flux assayPage 8 of 19
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7to those of the human digestive tract following oral route,
we conducted all the assays with digested samples only.
Other digested milk product controls were also tested for
their effects over this dose range on Caco-2 cell viability
and cell death (LDH release). At 500–2000 μg/ml, Caco-2
cells appeared to be resistant to the cell death/cytotoxic
effects (apoptosis/necrotic) by Enprocal D after 48 hours
as compared to other digested milk product controls. In
particular Heat SMP has significantly increased the apop-
tosis/necrotic index indicating the presence of unidenti-
fied potential anti-cancer bioactive peptides released
upon its digestion [11,12]. At higher doses (4000 and
8000 μg/ml) Enprocal (undigested and digested) induced
cell death and loss of viability in Caco-2 cells but not in
normal FHs 74 Int cells. Enprocal samples were found to
provide normal intestinal epithelial cell protection as no
cytotoxicity resulted towards FHs 74 Int cells after treat-
ment with Enprocal (undigested and digested) at 100–
8000 μg/ml tested in the LDH release assay. It has been
reported that an α-lactoalbumin complex from acid-pre-
cipitated human milk casein (MAL) induces apoptosis in
tumor cells (Caco-2 and HT-29) and immature cells, but
not in mature differentiated FHs 74 Int cells [34,35]. In
MTT cell proliferation assay, Enprocal D in a dose depend-
ent manner stimulated the selective proliferation of nor-
mal FHs 74 Int cells and this stimulation was significantly
(P < 0.001) more effective than positive control EGF. Due
to an absence of cytotoxicity effects against these cells our
results suggest that Enprocal is safe to be taken orally and
may prove beneficial to premature infant gut growth. Fur-
ther studies are needed to determine the mechanisms
involved in growth-promoting effect of Enprocal on fetal
small intestinal cells. Also the anti-cancer property of
Enprocal in Caco-2 cells at higher doses is a matter of an
interesting future investigation. The anti-cancer effect of
Enprocal may be attributed to the activity of its WPC'
components such as Lactoferrin, which have been shown
to inhibit tumour cell growth both in vitro and in vivo
[8,12,15,36] or the synergistic effect of WPC components
with vitamins and calcium [37].
Cell surface activation marker expression on the human THP-1 (PMA differentiated) macrophages for MHC-I and M C-II mole ules (A) nd co-stimulatory (CD80, D86 and D40) molecules (B) is modul ted by Enpr cal D and com-pared with other d geste milk pr duct controls in vitroFigure 7
Cell surface activation marker expression on the 
human THP-1 (PMA differentiated) macrophages for 
MHC-I and MHC-II molecules (A) and co-stimulatory 
(CD80, CD86 and CD40) molecules (B) is modulated 
by Enprocal D and compared with other digested 
milk product controls in vitro. Responses were measured 
by the upregulation of the surface markers CD80, CD86 and 
CD40. A negative control of cells without treatment is 
shown. Positive control of LPS and IFN-γ is shown. All treat-
ments were performed in triplicate and assay was repeated 
three times independently with similar results. The mean for 
each experiment was calculated and presented as a mean ± 
SD values. ** Indicates a highly significant P < 0.001 value 
from the control with media only. *Indicates a significant P < 
0.05 value from the control with media only.
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Antioxidant enzymes activities for copper zinc superoxide dismutase (CuZnSOD) and manganese superoxide dismutase (MnSOD) A), glutathione p roxidase (GPx), an  catalase CAT) (B) w re determi ed after treating Ca o-2 cells with 500 μg/ml of Enprocal D and compar d with oth r dige edmilk product co trolsFigure 6
Antioxidant enzymes activities for copper zinc super-
oxide dismutase (CuZnSOD) and manganese super-
oxide dismutase (MnSOD) (A), glutathione 
peroxidase (GPx), and catalase (CAT) (B) were 
determined after treating Caco-2 cells with 500 μg/
ml of Enprocal D and compared with other digested 
milk product controls. All data was compared with the 
levels of positive control (H2O2/Menadione). All treatments 
were performed in triplicate and assay was repeated three 
times independently with similar results. Data are expressed 
as mean ± SD. **P < 0.001 is the highly significant value from 
the control with media only. *P < 0.05 is the significance 
value from the control with media only.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7We further demonstrated that Enprocal improved gut cell
wall integrity, aided in macromolecular absorption. Dis-
ruption of the epithelial barrier in the gut is a hallmark of
gut inflammation and diseases. Failure of barrier function
in the gut epithelium is a key feature in the pathology of
diseases, such as leaky gut syndrome, IBD, cancer etc. [38].
Healthy intestinal tract acts a barrier against colonization
and/or translocation of pathogens and toxic compounds.
Diarrhoeal diseases as a result of gut infection caused by
Escherichia coli, Salmonella, Shigella, Campylobacter
jejuni, Entamoeba histolytica and rotavirus are one of the
important causes of infant mortality and morbidity in
developed and underdeveloped countries [39-41]. To
ensure monolayer integrity, TEER of Caco-2 polarised
monolayers grown on millicell cell culture inserts (Tran-
swell system) was measured using Millicell-ERS system
voltohm meter which measured the monolayer resistance
under aseptic conditions. Compared with other control
products, high TEER values were observed in monolayers'
treated with Enprocal D and P2 after 6 hours of treatment.
These values returned to baseline after 12 hours and after
24 hours TEER values went further up with only Enprocal
D treatment and which were maintained till 48 hours.
These observations indicate that there was no difference
between Enprocal D and P2 with regards to the functional
activities to gut cells following treatment at till 24 hours.
The gut cell integrity results were again confirmed by
expression of tight junction protein Zona Occludin (ZO-
2) on treated Caco-2 monolayers. Enprocal D and P2 as
compared to control products increased the expression of
tight junction protein -ZO-2.
In the gut permeability assay, Enprocal D aided macromo-
lecular transport studied by HRP-flux through the Caco-2
monolayer. The transport of nutrients across the intestinal
epithelium may occur by one or more of 4 different
routes: the passive transcellular and paracellular routes,
the carrier mediated route or by transcytosis. Caco-2 mon-
olayers have been world widely used to study drug trans-
port by all 4 pathways [26,27] and permeability through
Caco-2 cell monolayers correlates well with human in
vivo absorption [27]. The results of the HRP flux indicated
that HRP flow through increases with time after treatment
with Enprocal D and other digested control milk prod-
ucts. This was reflected in the increased flux of HRP across
the monolayers by the 4 hour point. All these results of
TEER, HRP-flux and ZO-2 expression clearly indicates that
Enprocal maintains the gut cell integrity even after diges-
tion and showed no side effect on its absorption and per-
meability through Caco-2 monolayer.
Enprocal treatment does not induce oxidative stress/injury
Increases in the levels of reactive oxygen species (ROS)
that may occur during periods of oxidative stress, appear
to be detected by redox-sensitive regulatory molecules in
the cell, triggering homeostatic responses to prevent cellu-
lar injury [21]. Among those responses is the regulation of
AOE, as the levels and balance of AOE modulate the sus-
ceptibility of the cell to oxidative injury. Highly reactive
free radicals formed by exogenous chemicals or endog-
enous metabolic processes in the human body or in food
systems are capable of oxidizing biomolecules, resulting
Inhibition of lymphocyte-epithelial (A) and monocyte-epithe-lial (B) cell adhesion by En rocal D and other diges d milk product c ntrolFigure 8
Inhibition of lymphocyte-epithelial (A) and mono-
cyte-epithelial (B) cell adhesion by Enprocal D and 
other digested milk product controls. For adhesion 
assays, Caco-2 cell monolayers, grown in 96-well plates, 
were treated for 18 h with Enprocal D and other digested 
milk product controls. CMFDA-labeled Jurkat (A) or THP-1 
(B) cells were then added. After incubation for 60 min at 
37°C, nonadherent immune cells were removed by washing 
with HBSS and the monolayer-associated Jurkat cells or 
THP-1 was counted. Values are showed as the percent inhi-
bition. All treatments were performed in triplicate and assay 
was repeated three times independently with similar results. 
The mean for representative experiment was calculated and 
presented as a mean ± SD values. ** Indicates a highly signifi-
cant P < 0.001 value from the control with media only. *Indi-
cates a significant P < 0.05 value from the control with media 
only.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7in cell death and tissue damage. In the gut, variations in
the activities of AOE have been reported under different
inflammatory/pathologic conditions associated with free
radical injury [31]. We examined the specific AOEs such as
CuZnSOD, MnSOD, GPx, and CAT activities in Caco-2
epithelial cell cultures treated with Enprocal D and other
digested milk product controls. With Enprocal D there
were no significant changes in the induction of AOE activ-
ity levels and were similar in effect to natural anti-oxidant
vitamin C used as a positive control. These results indi-
cated that no oxidative stress or free radical injury
occurred to the cells and these findings can be explained
on the basis of synergistic effects of Enprocal product for-
mulated with vitamin C, A, and Zn, the known anti-oxi-
dants.
Enprocal up-regulates the surface expression of co-stimulatory 
(CD40, CD80 and CD86) molecules and MHC I and II on human 
macrophages
Macrophages as antigen-presenting cells (APCs) play an
important role in innate immune response in the gut and
represent one of the first lines of nonspecific defence
against bacterial invasion. The macrophages are highly
responsive to their environment (biosensors) and relay
messages instructing other arms of the immune system
e.g., T cells and B cells, to respond in an appropriate way
[42]. These messages can be through costimulatory mole-
cules (present on the cell surfaces that facilitate direct
interactions between APCs and T cells) or soluble proteins
(cytokines). Even though cytokines play diverse roles in
regulating immune functions, some cytokines, e.g., tumor
necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 have
received more attention than others because they have tra-
ditionally been classified as proinflammatory and as such
are known to be associated with chronic inflammation
including IBD [5].
Recently an in vitro coculture system has been reported
that could be utilized for an assay to search for drugs or
food substances, which could prevent intestinal inflam-
mation [33]. To study the cell-to-cell interaction between
intestinal epithelial cells (Caco-2) and activated macro-
phages (THP-1), we utilized the similar Transwell model.
We used THP-1 cell line rather than primary human
monocytes or dendritic cells (DCs) to minimize the varia-
bility due to sample collection from different subjects.
DCs are considered to be highly sensitive and professional
APCs of the immune system [43], but they are difficult to
isolate and require careful handling to prevent them
becoming activated before treatment with any bioactive.
Thus, they can produce variable results [42]. We found
that digested Enprocal when added to apical (upper) wells
containing Caco-2, up-regulated the expression of "activa-
tion markers" (CD 40, CD80, and CD86 and MHC I &
MHC II) in PMA differentiated THP-1 macrophages cul-
tured in bottom (basolateral) wells. This implies that as
proposed in the hypothesis (working model) in Figure 9,
Enprocal components moved from the 'mucosal' to 'sero-
sal' side by any of the mechanisms shown and interact
with 'APC' to induce upregulation of costimulatory mole-
cules and aid gut-immune cell cross-talk.
The intestinal anti-inflammatory activity exerted by
Enprocal was characterized by a down-regulation of cell
adhesion of THP-1 and Jurkat E6-1 cells to Caco-2 monol-
ayers treated with digested samples of Enprocal and other
digested milk product controls in a static assay system.
Although these adhesion assays do not replicate the in
vivo conditions of dynamic gastrointestinal tract but these
heterotypic assays have been used earlier for the develop-
ment of immunomodulatory peptides [40]. Moreover it
has been reported that there are peripheral (systemic) tar-
get sites for the biologically active milk-derived peptides
that may be absorbed intact [reviewed in [11,12,44]] and
enter the circulation. In that situation this anti-inflamma-
tory activity of Enprocal may hold promise and clearly
more work needs to be done in adhesion assays using nor-
mal primary human immune and epithelial/endothelial
cells.
The intestinal intraepithelial lymphocytes and monocytes
are effector cells capable of secreting cytokines in response
to stimulation [45]. These cytokines include tumor necro-
sis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin
(IL)-1β, IL-2, IL-6 and IL-10, and it has been suggested
that IFN-γ and TNF-α can act directly on intestinal epithe-
lial cells to mediate changes in the epithelial permeability
and the capacity for electrogenic ion transport [46,47].
The mucosal to serosal movement of Enprocal D compo-
nents' in our coculture system led to modulation of the
cytokine secretion by monocytes and T-lymphocytes. In
Enprocal D-treated THP-1 cell supernates, despite the lev-
els of TNF-α and IL-1β being reduced, IL-6 (other proin-
flammatory molecule) secretion was not reduced to the
scale of WPC. IL-2 (well known for its stimulatory role in
T cell proliferation) secretion levels by Jurkat E6-1 cells
were significantly higher with Enprocal treatment. Both
IL-6 and IL-2 are important in the terminal differentiation
of B-cells into plasma cells [48]. Enprocal D significantly
enhanced the secretion of IFN-γ, and IL-10 compared to
the positive control PMA, WPC and P2 treated T-lym-
phocytes. IL-10 is considered anti-inflammatory which
inhibits the generation of cell mediated immune
responses. IL-10 is an interesting multifunctional cytokine
produced by T-cells, monocytes, and other cell types [49].
IL-10 enhances B-cell viability and augments the prolifer-
ation and differentiation of B-cells after stimulation
through the Ig receptor [49,50], therefore associated with
humoral or Type 2 immune responses. Overall, Enprocal
D provided the most consistent up-regulation of antiPage 11 of 19
(page number not for citation purposes)
BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7inflammatory cytokines and was the second most prolific
down-regulator of pro inflammatory cytokines. Enprocal,
through down-regulation of proinflammatory cytokines
such as TNF-α and IL-1β (both known to play an impor-
tant role in gut chronic inflammation), may prove benefi-
cial in IBD, CD & UC. TNF-α, in particular has been
recognized as playing a central role in the pathogenesis of
Crohn disease. Nevertheless, reducing the production or
effect of TNF-α in Crohn disease patients is believed to be
beneficial [51]. In fact, different drugs capable of interfer-
ing with the activity of TNF-α cytokine have been success-
fully developed for IBD therapy [52,53]. However, despite
earlier hopes, the results from studies using TNF-α antag-
onists were disappointing, and there were some reports of
severe complications [54].
Schematic drawing of a model on hypothesis of mechanism(s) of Enprocal's function in gut and immune healthFigure 9
Schematic drawing of a model on hypothesis of mechanism(s) of Enprocal's function in gut and immune 
health. Enprocal D working model depicting the activation of immune and strong gut cell integrity. 1 & 2) Oral administration 
and its digestion of Enprocal D maintains the human gut cell integrity and aids in gut cell proliferation with no cytotoxicity and 
no oxidative injury. 3) Modulation of Th1 and Th2 cytokine responses by Enprocal D appear to aid the production of antibod-
ies and gut immune functions. 4) By enhanced activation of immune responses, Enprocal thus, may prevent pathogen invasion. 
With the strong gut cell integrity and downregulation of proinflammatory cytokines such as TNFα and IL-1β, Enprocal D may 
help in the management of chronic gut inflammatory diseases such as inflammatory bowel disease (IBD) and leaky gut syn-
drome.
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7Conclusion
In conclusion, the schematic diagram shown in Figure 9
proposes a model (hypothesis) on mechanism(s) of
Enprocal's function in gut and immune health. Following
oral administration and upon digestion of Enprocal,
amino acids and potentially bioactive di and tri-peptides,
which may be released through enzymatic action from its
key ingredients such as whey protein concentrate, aid in
normal human intestinal cell proliferation with no cyto-
toxicity, maintain gut integrity, increase tight junction
protein expression, and enhance activation of immune
responses. Through modulation of the Th1 and Th2
cytokines responses Enprocal may aid the production of
antibodies and gut immune functions. These observed
effects of Enprocal however may arise not only from the
presence of dairy proteins but also from synergistic rela-
tionships with its other components in particular the
micro-nutrients. Strong gut cell integrity and activation of
immune cells with Enprocal may prevent infections
caused by pathogens or the invasion or entry of allergens.
Thus in future the detailed studies should be carried out
on efficacy of Enprocal in reducing individual pathogens
and gut cell interactions.
Stimulation of fetal intestinal cell proliferation without
cell cytotoxicity by Enprocal indicates that it may also be
given as infant food particularly for premature babies.
Although gut epithelial stem cells show no intrinsic limit
to their proliferative capacity but recent evidence
[reviewed in [55]] indicates that they suffer important
functional impairments associated with an altered pattern
of cellular response to DNA damage during the course of
ageing. In future studies, it would also be worthwhile to
determine whether consumption of Enprocal is effective
in preventing such functional damage to the stem cells in
the aged gut. Finally, our in vitro findings by employing
well characterized currently available and widely used cell
models may be relevant for gut and immune health of
consumer groups with special needs, such as infants and
the elderly. However future studies are needed to reveal
the potential of Enprocal as a formulated supplement that
produces defined effects on the human gut and immune
health.
Methods
Enprocal and other commercially available milk products
Enprocal and other commercially available control milk
products coded (P1 and P2) investigated in the study were
obtained from Warrnambool Cheese and Butter Factory
Company Holdings Limited (Victoria, Australia). The
Composition of Enprocal is given in Table 1. Heat-treated
skim milk powder (heat SMP) and whey protein concen-
Table 3: Effect of Enprocal D and other digested milk product controls on modulation of cytokine secretion determined by ELISA.
Cells Cytokines Enprocal D WPC P2 Media +cells Enzyme cocktail LPSa/PMAb
THP-1 cellsa IL-1β 305 ± 10** 180 ± 8** 120 ± 5** UD 700 ± 32c 710 ± 35
TNF-α 50 ± 2** 80 ± 2** UD UD 520 ± 27c 530 ± 28
IL-6 70 ± 5** 20 ± 2 10 ± 2 UD 114 ± 4c 125 ± 4
IL-8 1495 ± 15 1485 ± 12 1515 ± 16 UD 1500 ± 1c 1505 ± 15
Jurkat cellsb IL-2 905 ± 12 925 ± 10 535 ± 14** UD UDd 955 ± 15
IFN-γ 105 ± 5 40 ± 5* 10 ± 2 UD UDd 81 ± 5
IL-10 135 ± 10** 115 ± 10* 105 ± 6* UD UDd 91 ± 6
UD = undetectable levels.
aEnprocal digested and other digested milk product controls were added to Caco-2 cells in apical (upper) wells and culture supernatants were 
collected from the THP-1 (LPS stimulated) cells grown in basolateral (bottom) chamber after 8 hours (TNF-α) and 24 hours (IL-1β, IL-6 and IL-8) 
incubation.
bEnprocal digested and other digested milk product controls were added to Caco-2 cells in apical wells and culture supernatants were collected 
from the Jurkat cells grown in basolateral chamber. Supernatant from Jurkat cells stimulated with PMA was used as positive control for the 
measurement of IL-2, INF-γ and IL-10 cytokines.
cControl THP-1 cells with enzyme cocktail and with LPS stimulation.
dControl Jurkat cells with enzyme cocktail and without PMA stimulation.
Concentration of cytokines in the culture medium was determined by ELISA as described in the Methods section. Cytokine concentrations in 
negative control (untreated cells) and growth media only were below the detection limits. All samples were assayed in triplicate and three 
independent experiments were performed. The mean for all experiment was calculated and presented as a mean ± SD values.
** Indicates a highly significant P < 0.001 value from the control with positive control (LPS/PMA) only. *Indicates a significant P < 0.05 value from the 
control with positive control (LPS/PMA) only.Page 13 of 19
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BMC Immunology 2009, 10:7 http://www.biomedcentral.com/1471-2172/10/7trate 80 (WPC) were included as control milk products.
We cannot reveal the identity of other milk products P1
and P2 due to commercial reasons. Protein concentra-
tions were measured by Coomassie Plus-The Better Brad-
ford Assay kit (Endogen). Products were assayed for
lipopolysaccharide (LPS) contamination and the concen-
tration of endotoxin was < 0.13 μg/kg.
In vitro digestion
Enprocal and the control milk products were digested
with digestive enzymes cocktail mixture using a modified
protocol [56]. The enzyme concentrations in the commer-
cially available enzyme tablet are shown in Table 4. After
gastric phase digestion the solutions of protein fractions
and enzyme tablet were made for small intestinal phase in
0.1 M NaHCO3 solution pH 7.2. The reaction mixture was
set in 1:50 (enzyme: protein) ratio (standardized after pre-
liminary observations) and incubated at 37°C in a shaker
(250 rpm). Enzyme digests were collected after 1, 2, 4 and
6 hours incubation. The reaction was stopped by inacti-
vating the enzymes at 42°C and aliquots were stored at -
20°C till further use in cell culture studies. Digests were
analyzed by SDS-PAGE (reducing & denaturing) electro-
phoresis (Figure 1).
Intestinal epithelial cell culture
Caco-2 (human colon adenocarcinoma), and FHs 74 Int
(an adherent human primary fetal small intestinal) cell
lines were obtained from American Type Culture Collec-
tion (ATCC, Rockville) and cultured in their respective
media from ATCC as per its guidlines. Caco-2 cells were
cultured routinely in Eagle's Minimum Essential Medium
(EMEM) purchased from ATCC supplemented with 20%
(v/v) heat-inactivated fetal calf serum (Sigma). FHs 74 Int
cells were routinely grown in Hybri-Care Medium (ATCC:
46-X) supplemented with 30 ng/ml human recombinant
epidermal growth factor (EGF; Affinity Bioreagents) with
10% fetal bovine serum. All cell lines were grown at 37°C,
in an atmosphere of 5% CO2 and 95% relative humidity.
Cell Viability assays
Caco-2 and FHs 74 Int cells were incubated with various
concentrations of Enprocal (undigested) & digested
(Enprocal D) and other digested milk product controls for
48 hours. Cells were trypsinized to obtain a cell suspen-
sion and all adherent and floating cells were collected for
counting the live and dead cells under microscope follow-
ing trypan blue staining.
Lactate dehydrogenase (LDH) cytotoxicity assay
The cytotoxic effect of different test treatments on Caco-2
and FHs 74 Int was studied by a colorimetric LDH release
assay using a commercially available kit (Roche Applied
Science). This assay quantifies cell death and lysis based
on measuring the release of lactate dehydrogenase (LDH)
which is present within the supernatant following the loss
of membrane integrity. The assay was carried out as per
kit's instructions. Briefly, 2 × 103 cells per well (total vol-
ume 100 μL) were plated into a 96 well plate and incu-
bated for 24 hours at 37°C in 5% CO2. Following
incubation, growth media was replaced with fresh media
containing different concentrations of Enprocal (undi-
gested), Enprocal D (digested) and other digested milk
product controls, and cells incubated further for 48 hours.
Cytotoxicity measurements were tested at 48 hours after
treatment with Enprocal and other digested milk product
controls. Triton-X100 (1%V/V) was used as a high (posi-
tive) control and cells in media only was the low (nega-
tive) control. The amounts of lactate dehydrogenase
(LDH) in the supernatant were determined and calculated
as per kit instructions. All tests were performed in tripli-
cate and assay was repeated three times independently
with similar results.
Apoptosis versus necrosis
In order to detect the nature of cell death following treat-
ment with different test samples as well as to differentiate
between apoptosis and necrosis at single cell level, Caco-
2 and FHs 74 Int cells were plated at a density of 1 × 104
cells on 8 well slides and grown for two days at 37°C with
5% CO2. Following media removal, the cells were then
treated with different concentrations of Enprocal D and
other digested milk product controls (in triplicates) in
serum free media for 48 hours. As a positive control,
apoptosis inducing anti-cancer drug Paclitaxel (BioVi-
sion), was added to the cells (final concentration of 20
nm). After 48 hours the media was removed and apop-
totic cells were determined by TUNEL staining using an in
situ apoptosis detection kit from Boehringer Mannheim
as per kit instructions [57]. Slides were also stained with
propidium iodide (Sigma-Aldrich) to distinguish necrotic
cells from those undergoing apoptosis. Same slides were
counterstained with methylene blue-staining and
Table 4: Digestive enzyme cocktail ingredients.
Pancreatin (4×) 1250 mg
Papain 150 mg
Bromelain 150 mg
Trypsin 125 mg
α-Chymotrypsin 3 mg
Lipase 50 mg
Amylase 50 mg
Rutin 100 mgPage 14 of 19
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was counted. The apoptotic and the necrotic indices were
calculated as follows: Apoptotic index (A/I) or necrotic
index (N/I) = number of apoptotic or necrotic cells × 100/
total number of nucleated cells. Following treatments,
another kit, Annexin-VFLUOS staining (Roche Applied
Science), was also used to differentiate apoptotic cells
from necrotic cells, as per manufacturer's instructions.
This assay is based on principle that phosphatidyl serine,
located in the inner leaflet of the cell membrane, is
exposed at the cell surface in the early stage of apoptosis.
Annexin V shows high-affinity for phosphatidyl serine-
binding that makes it a useful selective and powerful tool
for detection of apoptotic cells [58].
Cell proliferation (MTT) assay
Human intestinal cell lines Caco-2 and FHs 74 Int were
seeded each into 96 well plates, at a density of 2 × 103 cells
per well (total volume 100 μL) and incubated for 24 hours
at 37°C in 5% CO2. After removal of media, the cells were
incubated with fresh growth media containing different
concentrations of Enprocal and other digested milk prod-
uct controls, for 48 hours. As a positive control EGF 50 ng/
ml was used. The effect of different treatments on cell pro-
liferation of Caco-2 and FHs 74 Int cells was compared in
treated versus untreated cells with the use of commercially
available 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay Kit (R&D systems). The
assay was carried out as per manufacturer's instructions.
All tests were performed in triplicate and assay was
repeated three times independently with similar results.
Measurement of transepithelial resistance (TEER)
Mucosal integrity of Caco-2 cells seeded onto Milicell cell
culture inserts (Millipore Australia) in 24-well plates was
studied by measuring the transepithelial electrical resist-
ance (TEER) with a Millicell-ERS voltohm meter (Milli-
pore Australia). The device contained a pair of chopstick
electrodes (which facilitated the measurements) and
measures membrane potential and resistance of epithelial
cells in culture. It does this by qualitatively measuring cell
monolayer health and cell confluency [59]. Caco-2 cells
were seeded at a density of 4 × 103 per well in the volume
of 200 μl growth medium (EMEM plus 20% fetal bovine
serum) added to the apical well of insert and 800 μl of
growth medium was added to the basolateral well in 24-
well tissue culture plates for incubation. To obtain mon-
olayer, cells were grown for 21 days and medium was
replaced every third day. After 21 days the monolayers
were thoroughly checked for any gaps under the micro-
scope in order to prevent any false TEER readings. The dif-
ferentiation was characterized by a polarization of the
monolayer with formation of domes. These filter-grown
monolayers were first equilibrated with serum free growth
medium (EMEM containing GIBCO's antibiotic-antimy-
cotic supplement for 2 hours under cell culture condi-
tions. TEER was measured at the start of experiment i.e.
before the addition of Enprocal D and other digested milk
product controls. Each preparation was added to the api-
cal compartment in serum free growth medium, and Tri-
ton-X, was used as a positive control. All test and control
samples were added in triplicate. Cell monolayers were
incubated at 37°C, 5% CO2 and 90% humidity and TEER
was measured at specific intervals (6, 12, 18 and 24 hours)
and at the end of experiments (48 hour). The monolayers
were incubated at 37°C in 5% CO2 and 90% humidity
between measurements.
Horseradish peroxidase (HRP) flux
Caco-2 cells were seeded on to Millicell cell culture inserts
at a density of 4 × 103 per well and grown as monolayers
for up to 21 days as described above. Following medium
removal, the cells were equilibrated for 2 hours with
Hanks Balanced Salt Solution (HBSS) without phenol red
(Invitrogen) and then treated with Enprocal D and other
digested milk product controls. Horseradish peroxidase
(HRP-Sigma-Aldrich) was added to the apical side of the
monolayer at a final concentration of 0.15 mg/ml [60].
Following incubation at 37°C in 5% CO2 and 90%
humidity, the flux of HRP was measured at 4, 8 and16
hours incubation, by taking 25 μl from the apical com-
partment and 300 μl from the basolateral compartment.
The HRP activities were then measured in aliquots of these
samples by treating the samples with 3,3',5,5'-tetrameth-
ylbenzidine (TMB; Sigma-Aldrich) which is an HRP sub-
strate and then measuring the absorbance of the samples
using an ASYS Expert plus UV ELISA plate reader at 450
nm. All treatments were performed in triplicate and assay
was repeated three times independently with similar
results.
Immunofluorescence staining for ZO-2 tight junction 
protein
Caco-2 cells were grown on sterile 8 chamber slides (BD
Sciences) with seeding density of 1 × 104 cells/ml. After 5
days of growth monolayers, were equilibrated with serum
free medium and then treated with Enprocal D and other
digested milk product controls as well as 1% Triton-X
(positive control) for 12 hours. Monolayers were washed
with PBS (pH 7.2), fixed in 4% paraformaldehyde (in
PBS; pH 7.2) for 15 minutes at room temperature (RT)
and blocked for 30 minutes in 2% normal rabbit serum
(Vector labs) in PBS. After 3 PBS washes monolayers were
incubated with mouse monoclonal anti-ZO-2 (Invitrogen
diluted 1:1000 in PBS containing 1% BSA) overnight at
4°C. Secondary anti-mouse IgG-FITC antibody (diluted
1:100 in PBS; Sigma-Aldrich) was used to detect the pri-
mary antibody staining (1 hour incubation at RT). After 3
PBS washes, chambers were removed from the slide and
mounted with one drop of Vectashield mountingPage 15 of 19
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ondary antibody controls, cells were stained as above
except incubation with PBS containing 1% BSA was car-
ried out at appropriate staining steps. The slides were then
viewed with Leica TCS SP5 confocal system fitted with
inverted DMI 6000 microscope. Images were collected
with LAS AF software. These images were then processed
in Adobe Photoshop CS3.
Antioxidant enzyme (AOE activity assays
For each assay Caco-2, 2 × 104 cells/well were grown in 6
well plates for 24 hours and then treated with Enprocal D
and other digested milk product controls for 48 hours.
Following incubation, cells were isolated in assay buffer
and lysed by a freeze-thaw cycle. The debris was removed
by centrifugation at 8000 × g for 5 min at 4°C, and the
protein content of each sample was determined using the
Coomassie Plus – The Better Bradford™ Assay Kit
(Endogen). AOE activity assays were carried out spectro-
photometrically by the methods as described earlier for
superoxide dismutase (SOD) [61], glutathione peroxidase
(GPx) [62] and catalase (CAT) [63]. All treatments were
performed in triplicate and assays were repeated three
times independently with similar results.
Superoxide dismutase (SOD) activity assay
To the assay mixture containing 0.1-mM cytochrome c,
0.05-mM xanthine, and KCN (10 μM for total SOD activ-
ity, 3 mM for MnSOD activity) in phosphate buffer, 150-
μg protein (for each sample) was added in a final volume
of 3 ml. After zeroing (blanking), xanthine oxidase was
added to a final concentration of 0.6 U/ml, and the
change in absorbance at OD at 550 nm was recorded at
regular intervals over 4 min. A standard curve for SOD was
generated and enzyme activity was determined by com-
paring samples to a standard curve of known SOD activ-
ity. Cu,Zn-superoxide dismutase (CuZnSOD), activity was
calculated as the difference between total SOD activity
and Mn-superoxide dismutase (MnSOD) activity [61].
Glutathione peroxidase (GPx) activity assay
For GPx enzyme activity measurements aliquots of pro-
tein samples (140 μg of protein) were added to the assay
mixture containing 1 U/ml glutathione reductase and 2
mM glutathione in 1 ml of phosphate buffer after 30 min
incubated at 37°C for 30 min. Nicotinamide adenine
dinucleotide phosphate and tert-butylhydroperoxide
were added to final concentrations of 580 μM, respec-
tively, and the change in absorbance at OD at 340 nm was
recorded at regular intervals over 4 min. The amount of
GPx required to oxidize 1 μmol nicotinamide adenine
dinucleotide phosphate in 1 min at 25°C was defined as
enzyme units and calculated on the basis of a molar
absorptivity for nicotinamide adenine dinucleotide phos-
phate at 340 nm of 6.22 × 10-6 [62].
Catalase (CAT) activity assay
CAT enzyme activity was measured by monitoring the
decrease in H2O2 concentration spectrophotometrically
over time. For each sample, 130 μg protein was added to
50-mM phosphate buffer in a quartz cuvette and, after
blanking, H2O2 was added to a final concentration of 10
mM in 0.9 ml, and the absorbance at OD at 240 nm was
recorded at regular intervals over 4 min. The specific activ-
ity of each sample was calculated based on activity of pure
CAT as described earlier [63].
Immune cell culture
THP-1 and Jurkat clone E6-1 obtained from American
Type Culture Collection (ATCC Rockville, MD) were
employed in immune assays. THP-1 cells are human mye-
lomonocytic cell line that is widely used to study mono-
cyte/macrophage biology in cell culture systems and
Jurkat cells are human T lymphocyte (T cell leukemia).
THP-1 cells were cultured and maintained in RPMI 1640
(Gibco-BRL), supplemented with 10% heat-inactivated
fetal calf serum, 2 mM L-glutamine, 0.05 mM 2-mercap-
toethanol,100 U/ml penicillin, and 100 μg/ml streptomy-
cin (complete RPMI 1640). Jurkat E6-1 cells were
routinely grown in suspension in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin.
Monocyte/lymphocyte-epithelial adhesion assay
Adhesion assays were performed with THP-1 and Jurkat
E6-1 cells under static conditions by the methods as
described earlier [32,64] with modifications. For static
adhesion assays Caco-2 cells were seeded at a density of 2
× 104 cells per well (total volume 100 μL) and grown as
confluent monolayers in 96-well plates and preactivated
with IL-1β 10 ng/ml overnight before adhesion assay.
Washed monolayers were then treated for 18 h with
Enprocal D and other digested milk product controls. Epi-
thelial cells were washed twice with culture medium
before addition of 100 μl (1 × 105) labeled THP-1 or Jur-
kat E6-1 cells per well. Both THP-1 and Jurkat E6-1 cells
were labeled with the fluorescent dye chloromethyl fluo-
rescein diacetate (CMFDA; Molecular Probes, Oregon) at
37°C for 30 min [64]. The plates were incubated for 60
min at 37°C. After incubation, the monolayer was gently
washed three times with PBS to remove non adherent
cells. Fluorescence-labeled adherent cells were counted
under fluorescent microscope in minimum of 5 fields.
Cell surface marker staining
We employed a coculture model to examine the effect of
Enprocal D treatment on the interaction between gut-
immune cells. For the coculture experiments THP-1
monocytic cells were grown in 24-well plates at a density
of 5 × 105 cells/well and differentiated into macrophage-Page 16 of 19
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acetate (PMA; Sigma-Aldrich) for 4 days [33]. The differ-
entiated status was confirmed on the basis of morphology
and staining for the expression of leukocyte integrin
CD11b (macrophage-1 antigen) (data not shown). The
semipermeable support membrane (Milicell cell culture
inserts from Millipore) on which the intact Caco-2 cell
monolayers had been cultured for 21 days was placed on
the differentiated THP-1 cells that had been cultured on
the 24-well plates. After starting the coculture for 18
hours, apical media was removed and Caco-2 cells were
treated with fresh growth media containing Enprocal D
and other digested milk product controls. Control treat-
ments included cells in medium only (negative control),
enzyme cocktail. Interferon-γ (IFN-γ) at a concentration of
5 ng/ml was added to the positive control wells on the
basolateral compartment containing differentiated THP-1
cells. Cells were incubated at 37°C with 5% CO2 for 24 h
and cell surface marker staining was determined by direct
immunofluorescence in paraformaldehyde fixed (4% PF
in PBS pH 7.2; 15 minutes at RT) cells. Cells were incu-
bated for 1 hour at room temperature with FITC labeled
antibodies to anti-human CD40, CD86, CD80, major his-
tocompatibility complex (MHC) I & II (PharMingen and
R&D Systems). Following washing with PBS buffer wells
were mounted with one drop of Vectashield mounting
medium with DAPI (Vector Labs). For primary and sec-
ondary antibody controls, cells were stained with PBS
containing 1% BSA (no primary antibody). The presence
of labeled cell surface markers was counted under the flu-
orescence microscope and percentage of positive cells was
calculated from total number of cells (DAPI positive).
Cytokine ELISA
In the Caco-2 THP-1 coculture model, cytokine levels
were measured in the supernatant of LPS stimulated THP-
1 cells grown in the lower chamber for 8 and 24 hours
after the addition of Enprocal D and other digested milk
product controls to Caco-2 cell monolayers in the upper
chamber [33]. Briefly, THP-1 cells were grown and main-
tained in endotoxin free complete RPMI-1640 at the expo-
nential phase. To increase the sensitivity to LPS, cells were
stimulated with 5 ng/ml human recombinant IFN-γ (Bio-
Vision >98% with endotoxin level < 0.1 ng per μg of IFN-
γ) for 16 hours [65,66]. Following incubation cells were
centrifuged, re-resuspended in serum free medium and
seeded in 24 well plates with final cell concentration of 8
× 105 cells per well. Caco-2 monolayers (21 days old)
grown and differentiated on the Milicell cell culture
inserts (Millipore) were placed on the wells containing
THP-1 cells in 24-well plates. All cells were allowed to set-
tle for 1 h and following removal of apical media, Enpro-
cal D and other digested milk product controls were
added to the Caco-2 cells in fresh growth media 30 min-
utes before LPS (50 ng/ml; E. coli, Sigma-Aldrich) was
added to the THP-1 cells (lower basolateral chamber).
Supernatants were collected after 8 (for TNF-a) and 24
hours for other cytokines at 37°C with 5% CO2 Supern-
ants of Jurkat E6-1 cells grown in coculture with Caco-2
were used to determine the protein levels of IL-2, IL-10
and IFN-γ cytokines. Jurkat E6-1 cells were kept in the
exponential growth phase by passages at 2–3 days inter-
vals. As described above, Caco-2 monolayers (21 days
old) grown and differentiated on the Milicell cell culture
inserts (Millipore) were placed on the wells containing
2.5 × 105cells/ml Jurkat E6-1 cells grown overnight. After
one hour incubation, apical media was replaced with
media containing Enprocal D and other digested milk
product controls and incubated for 24 hours. PMA (20
ng/ml) was used a positive control. Jurkat cell superna-
tants were obtained via centrifugation at 4°C and stored
at -80°C until cytokine analysis.
Amounts of the cytokines TNF-a, IL-1β, and IL-6 and IL-8,
IL-2, IL-10 and IFN-γ in cell culture supernatants were
determined by using Biotrak Easy ELISA kits (Amersham
Biosciences) for human cytokines. The limits of detection
of the assays were 2.5 pg/ml for TNF-a, 1.1 pg/ml for IL-
1β, 1.4 pg/ml for IL-6, < 7.26 pg/ml for IL-8, 3.5 pg/ml for
IL-2, 1 pg/ml for both IFN-γ and IL-10. Each assay proto-
col was carried out as per kit instructions using cytokine
standards supplied with kit. Samples were run in triplicate
and experiments were performed three times. The concen-
tration of cytokines was determined by the standard curve
using linear regression curve fit method.
Data interpretation and statistical analysis
For the statistical evaluation of numerical data, one way
ANOVA and Students t-test were used to compute the dif-
ferences. In all cases, P < 0.05 and P < 0.001 were taken to
identify levels of significance.
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